ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

December 1, 2026

Study Completion Date

October 1, 2028

Conditions
IgM MGUSWaldenstrom MacroglobulinemiaNeuropathy;Peripheral
Interventions
DRUG

Acalabrutinib

Dose per protocol, oral twice daily per cycle

DRUG

Rituximab

Premedications (including acetaminophen, an antihistamine, and a steroid) will be given per institutional guideline Dosage determined per protocol and cycle timepoint, Route IV or SQ per protocol and cycle timepoint, schedule per protocol and cycle timepoint

Trial Locations (2)

02214

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Shayna Sarosiek, MD

OTHER